InsiderTrades

Form 4 for NVCR NovoCure Ltd

Accepted 2024-02-29 00:00:00 ET · period of report 2024-02-27 · accession 0001562180-24-001988 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2024-02-29 2024-02-27 NVCR Leonard Frank X EVP, Pres, Novocure Oncology A - Grant $16.30 +102.2K 164.7K +164% +$1.67M
D 2024-02-29 2024-02-28 NVCR Leonard Frank X EVP, Pres, Novocure Oncology S - Sale $16.14 -2,078 162.6K -1% -$33.5K
D 2024-02-29 2024-02-27 NVCR Leonard Frank X EVP, Pres, Novocure Oncology A - Grant $16.30 +156.3K 156.3K New +$2.55M

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Ordinary Shares 2024-02-27 A A 102,249 $16.30 164,695 D — — (F1) Represents restricted share units that are scheduled to vest in equal installments on February 27, 2025, 2026 and 2027, subject to the reporting person's continued employment through such dates.
2 Common Ordinary Shares 2024-02-28 S D 2,078 $16.14 162,617 D — — (F2) Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
3 Derivative Stock Options (Right to buy) 2024-02-27 A A 156,348 $16.30 156,348 D $16.30 · 2025-02-27 to 2034-02-26 156,348 Ordinary Shares (F3) Options to buy 156,348 ordinary shares will vest in equal installments on each of February 27, 2025, 2026, 2027 and 2028, subject to the reporting person's continued employment through such dates.